JAK Inhibitors for Alopecia Areata: Baricitinib, Ritlecitinib and Deuruxolitinib, Trial by Trial

Who This Is For#

This guide is for you if:

• You have extensive alopecia areata and a dermatologist has mentioned a JAK inhibitor
• You have read the alopecia areata guide and want the trial numbers behind the three approved drugs
• You are weighing the boxed warning and want to know which trial it comes from
• You are already on one of these drugs and want to understand the monitoring and what stopping means

This guide is NOT for you if:

• Your hair loss is gradual, at the crown or temples, and runs in the family (see androgenetic alopecia)
• You are shedding diffusely after illness, surgery, childbirth or stress (see telogen effluvium)
• Your scalp is scarred, red, scaly or painful where the hair is gone (see scarring alopecia types and a dermatologist promptly)
• You have small patches and have not yet seen a dermatologist (start with when to see a dermatologist)

How a JAK Inhibitor Works in Alopecia Areata#

Alopecia areata, an autoimmune, non-scarring hair loss affecting 2% of the United States population, is a CD8 T-cell driven disease in which the cytokines interferon-gamma and interleukin-15 play a central role [4]. Those cytokines act through Janus kinase (JAK) signaling, the pathway these drugs block [11].

The drugs differ in which JAKs they block. Baricitinib is a JAK1 and JAK2 inhibitor [11] and deuruxolitinib a JAK1/JAK2 inhibitor [3]; JAK2, with its ubiquitous expression, can cause adverse effects, unlike JAK3, which is exclusively associated with the γc cytokine receptor [11]. The sources reviewed for this article do not describe ritlecitinib's target profile.

The class works; the questions are how well, and for whom#

A 2023 systematic review pooled seven RCTs with 1710 patients and found JAK inhibitors lowered the SALT score against placebo by a mean difference of -34.52 (95% CI, -37.80 to -31.24), rated moderate certainty [6]. The pivotal trials below say how much, in whom, and by when.

The Three Drugs, Trial by Trial#

All three programs used the Severity of Alopecia Tool (SALT), which runs from 0 (no scalp hair loss) to 100 (complete scalp hair loss) [1]. Each primary outcome was SALT 20 or less, meaning most of the scalp had regrown.

Baricitinib: BRAVE-AA1 and BRAVE-AA2#

Two randomized, placebo-controlled, phase 3 trials enrolled adults with severe alopecia areata and a SALT score of 50 or higher (654 in BRAVE-AA1, 546 in BRAVE-AA2), assigned 3:2:2 to once-daily baricitinib 4 mg, 2 mg, or placebo [1]. At week 36, the 4-mg dose beat placebo by 32.6 percentage points in both trials, P<0.001 for each dose [1]. Acne, elevated creatine kinase and raised LDL and HDL cholesterol were more common with baricitinib, and the authors said longer trials are required to assess efficacy and safety [1].

Ritlecitinib: ALLEGRO#

ALLEGRO, a randomised, double-blind, multicentre, phase 2b-3 trial, randomized 718 patients aged 12 years and older with at least 50% scalp hair loss to once-daily treatment for 24 weeks [2]. At week 24, 38 (31%) of 124 patients on 200 mg + 50 mg and two (2%) of 130 on placebo had a SALT score of 20 or less; the lower-dose arms fell between them (see table) [2]. Up to week 48, adverse events had been reported in 82% of the 200 mg + 50 mg group, and there were no deaths [2].

Deuruxolitinib: THRIVE-AA1#

THRIVE-AA1, a phase 3 randomized, double-blinded, placebo-controlled trial, assigned patients aged 18-65 years with 50% or more hair loss to deuruxolitinib 8 mg twice daily, 12 mg twice daily, or placebo for 24 weeks [3]. The primary endpoint was met by 29.6% on 8 mg and 41.5% on 12 mg, versus 0.8% on placebo [3]. Most adverse events were mild or moderate, and the authors called for further studies of longer-term safety and the impact of treatment cessation [3]. The FDA approved deuruxolitinib in July 2024, the third oral JAK inhibitor for severe alopecia areata in adults [4]. We did not locate its companion trial, THRIVE-AA2, as a separate publication and print no figures for it.

Severity is the entry ticket, and the percentages are not a ranking#

Every pivotal trial required at least half the scalp bare: SALT 50 or higher for baricitinib [1], at least 50% scalp hair loss for ritlecitinib [2], and 50% or more for deuruxolitinib [3]. The trials say nothing about limited patchy disease, which the alopecia areata guide covers. Only ALLEGRO enrolled adolescents, and only the Litfulo label is indicated for adults and adolescents 12 years and older [2][8]; baricitinib and deuruxolitinib are approved for adults [4][11]. The baricitinib trials were adults only and THRIVE-AA1 capped enrollment at 65 [1][3].

Resist ranking the drugs by top-line percentage. Baricitinib was measured at week 36, the other two at week 24 [1][2][3], and the prescribable dose is set by each label, not by the best trial arm. What the trials share: all three cleared placebo convincingly, and in every trial most patients on active drug had not reached SALT 20 or less by the primary timepoint.

The Boxed Warning and the Trial It Rests On#

Olumiant, Litfulo and Leqselvi each carry a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events (MACE) and thrombosis [7][8][9]. In the Olumiant label's wording:

• Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB) [7]
• Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients [7]
• Malignancies have occurred in patients treated with OLUMIANT. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in RA patients [7]
• Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients [7]
• Thrombosis has occurred in patients treated with OLUMIANT. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers [7]

"Another Janus kinase inhibitor vs. TNF blockers" points to one trial.

What ORAL Surveillance found#

ORAL Surveillance was a randomized, open-label, noninferiority safety trial in active rheumatoid arthritis patients aged 50 or older with at least one additional cardiovascular risk factor, randomized to tofacitinib 5 mg or 10 mg twice daily or a TNF inhibitor [5]. Over a median follow-up of 4.0 years, MACE and cancer were higher with the combined tofacitinib doses (3.4% and 4.2%) than with a TNF inhibitor (2.5% and 2.9%); hazard ratios were 1.33 (95% CI, 0.91 to 1.94) for MACE and 1.48 (95% CI, 1.04 to 2.09) for cancers, and noninferiority was not shown [5]. Opportunistic infections, including herpes zoster and tuberculosis, and nonmelanoma skin cancer were also higher with tofacitinib [5].

A warning borrowed from a different drug, disease and population#

The trial tested tofacitinib, not any of the three alopecia drugs, in older rheumatoid arthritis patients selected for cardiovascular risk [5]; the FDA extended the finding across the class, and the labels say so in the words "another JAK inhibitor" [7][9].

That cuts both ways. The alopecia trials are not proof of cardiovascular or cancer safety: efficacy trials of a few hundred patients each, with primary endpoints at 24 or 36 weeks and safety follow-up of no more than 48 weeks, were not designed to detect those events [1][2][3]. Equally, the ORAL Surveillance percentages are not the personal risk of a young adult with no cardiovascular risk factors. The meta-analysis found JAK inhibitors were not associated with more treatment-related adverse events than placebo (RR, 1.25 [95% CI, 1.00-1.57]; high certainty) [6], which is reassuring about the trial window and silent about the years after it. Age, smoking, cardiovascular history, prior cancer and clotting history are what a dermatologist weighs against the label; bring them to the appointment.

Laboratory Monitoring the Labels Require#

The specifics differ by label:

• Olumiant (baricitinib): the label names absolute lymphocyte count (ALC), absolute neutrophil count (ANC) and hemoglobin, with thresholds by indication [7].
• Litfulo (ritlecitinib): ALC and platelet counts are recommended before treatment initiation and at 4 weeks after treatment initiation, and thereafter according to routine patient management [8].
• Leqselvi (deuruxolitinib): perform a CBC prior to and periodically during treatment [9]. Interruption thresholds are ALC below 500 cells/mm³, ANC below 1000 cells/mm³ and hemoglobin below 8 g/dL [9]. Treatment was associated with increases in triglycerides and total cholesterol [9].

Lipids also rose with baricitinib in the phase 3 trials [1]; the hair loss blood tests guide explains what a CBC and lipid panel measure.

Labs recur, and pregnancy belongs in the first conversation#

Because these drugs are taken continuously (next section), monitoring is a schedule, not a one-off screen. The labels also address pregnancy: Leqselvi's says to advise pregnant women of the potential risk to a fetus and to consider pregnancy planning and prevention for females of reproductive potential [9]; Litfulo's documents animal reproduction studies showing fetotoxicity and fetal malformations at significant exposures [8]. The Olumiant label text reviewed for this article did not include the pregnancy section; that means only that it was not retrieved, not that the label lacks one. Anyone who could become pregnant should raise this before the first tablet.

What Happens When You Stop#

The pivotal trials were not built to answer this. A narrative review concludes that the response is not sustained after discontinuation, with many studies showing a high recurrence rate with tofacitinib and ruxolitinib [11]. The only quantified relapse figure in the sources reviewed comes from a meta-analysis of those older off-label drugs: across 12 observational studies of 346 patients, recurrence was observed within three months after discontinuation in the majority (74%) [10]. We could not locate a published withdrawal or long-term-extension analysis for the three approved drugs through PubMed, so we print no relapse rates for them.

Real-world data cover people who stayed on baricitinib: in a 48-week cohort, 63.2% achieved SALT of 20 or less [12], and 55.6% of 36 patients who continued for 104 weeks in a single-institution retrospective analysis reached the same mark [13]. Both describe patients still on the drug; neither says what happens after it is stopped.

Treat it as maintenance, not a course#

These drugs behave like a treatment you stay on, not a course you complete, which makes the boxed warning a potentially multi-year exposure with recurring labs, not a 24-week one. Whether and when to attempt a taper is your dermatologist's call, informed by how long you have been in remission and what a relapse would cost you. Do not stop on your own; talk to the prescriber first, and keep a photo record so any change is measured, not guessed.

Oral vs Topical JAK Inhibitors#

Could a JAK inhibitor applied to the scalp deliver the benefit without the systemic warning? On current evidence, no, and the gap is wide.

In the 2023 meta-analysis, oral JAK inhibitors were more efficient than placebo (change from baseline SALT scores: MD, -36.80; 95% CI, -39.57 to -34.02), and no difference was found between external JAK inhibitors and placebo (MD, -0.40; 95% CI, -11.30 to 10.50) [6]. The best-designed topical trial agrees: a double-blind, randomized, vehicle-controlled phase 2 study found no significant difference in hair regrowth between 1.5% ruxolitinib cream and vehicle in part B [15].

The sources reviewed include one positive topical study, and its design is why it does not change the conclusion: a prospective, non-blinded, intrasubject vehicle-controlled study of a compounded 2% tofacitinib citrate ointment in 30 patients, in which 40% achieved an excellent response (>50% change in SALT score) over six months [14]. The authors themselves called the sample small and the follow-up too short to study relapse [14].

Topical is where the evidence is thin, not where the risk disappears#

If a clinic offers a compounded topical JAK inhibitor, the fair summary is: pooled RCTs show no difference from placebo [6], the one rigorous cream trial was negative [15], and the one positive study was small and unblinded [14]. Systemic absorption from a compounded ointment is not characterized in these sources, so "topical" should not be read as free of the boxed-warning concerns.

Frequently Asked Questions#

Related Resources#

• Alopecia Areata: Types, Treatment, and Outlook
• When to See a Dermatologist for Hair Loss: Red Flags
• Hair Loss Blood Tests: What to Request and Why
• Tracking Hair Loss Progress: Photo Guide
• Scarring Alopecia Types and Management: Complete Guide
• Emotional Impact of Hair Loss: Support Guide for Women